Program
ECC0509
A development code.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Liver Diseases, led by Eccogene.
Furthest: phase 2, since Dec 15, 20253 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eccogene | 32 open or running | phase 2since Dec 15, 2025 | Jul 22, 2021 | Mar 2027phase 1 · NCT07873229 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 22, 2021First study: phase 1 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT05012423 · 89 enrolled · Australia
- Dec 15, 2025Phase 2 study in Liver DiseasesPhase 2 reachedNCT07288138 · 160 planned · United States
- Sep 16, 2026Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT07873229 · 40 planned · Australia
Ahead
- Mar 2027Primary completion: phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT07873229
- Sep 15, 2027Primary completion: phase 2 study in Liver DiseasesNCT07288138
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07873229Non-alcoholic Fatty Liver Disease · Australia | 1 | Not yet recruiting | Mar 2027 | 40 |
| NCT07288138Liver Diseases · United States | 2 | Recruiting | Sep 15, 2027 | 160 |
| NCT05012423Non-alcoholic Fatty Liver Disease · Australia | 1 | Completed | Jul 22, 2023 | 89 |
How it is read
Names in the registry
- “ECC0509”, 4 entries
Codes read as this program: ECC0509.
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 2 studies
- Liver Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.